• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Pharma
    • Vaccines
    • Asia
    • Cell & Gene Therapy
    • Drug Delivery
    • Executives
  • Manufacturing
    • Facilities
    • Recalls
    • Warning Letters
  • Marketing
  • Special Reports
  • Fierce 50
    • Special Report
    • Awards Gala
  • Trending
    • Oncology
    • Supply Chain
  • Awards
    • Outsourcing Awards
    • Innovation Awards
    • Pharma Marketing Awards
  • Resources
    • Podcasts
    • Fierce Events
    • Industry Events
    • Webinars
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Pharma
    • Vaccines
    • Asia
    • Cell & Gene Therapy
    • Drug Delivery
    • Executives
  • Manufacturing
    • Facilities
    • Recalls
    • Warning Letters
  • Marketing
  • Special Reports
  • Fierce 50
    • Special Report
    • Awards Gala
  • Trending
    • Oncology
    • Supply Chain
  • Awards
    • Outsourcing Awards
    • Innovation Awards
    • Pharma Marketing Awards
  • Resources
    • Podcasts
    • Fierce Events
    • Industry Events
    • Webinars
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

initial public offering

new york stock exchange
Pharma

Veradermics locks in $256M IPO, shares spike

With an oversubscribed trading debut now in the books, Veradermics is well coiffed to tap into the growing opportunity for pattern hair loss drugs.
Fraiser Kansteiner Feb 5, 2026 10:01am
China Chinese Flag draped over gold bars economy stock market finance

Visen Pharmaceuticals files for $86M IPO in Hong Kong

Mar 21, 2025 7:05am
Asia

AstraZeneca, Takeda, BioNTech—Fierce Pharma Asia

Nov 10, 2023 8:05am
Close-up of syringe and vial

Schott has carved out a standalone business for its pharma unit

Aug 1, 2022 3:14pm
Asia Map

Hansoh, J&J, Brii and more—Fierce Pharma Asia

Oct 22, 2021 5:46am
Nasdaq

Cingulate seeks $58M to develop extended-release ADHD drugs

Sep 14, 2021 7:35am

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Biotech
    • Fierce Healthcare
    • Fierce Pharma
  • Our Events
    • Life Sciences Events
©2026 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings